Live Breaking News & Updates on China Based Qilu Pharmaceutical

Stay updated with breaking news from China based qilu pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

1 cancer drug in shortage nearing 100% resupply, White House says

The White House has announced that the shortage of cisplatin, a drug used to treat multiple types of cancer, is close to ending. ....

White House , District Of Columbia , United States , American Society Of Health , White House Office Of Science , Intas Pharmaceuticals , China Based Qilu Pharmaceutical , American Society , Health System Pharmacists , White House , Intas Pharmaceuticals , Cancer Centers ,

Connecticut doctors struggle with nationwide cancer drug shortages

Oncologists are reviewing options to space out treatments, safely reduce dosage or find substitutes ....

United States , Glenna Dejong , Peter Yu , Robert Louie , Dinesh Kapur , Roy Herbst , Intas Pharmaceuticals , Oncology Associates In Norwich , Drug Administration , Qilu Pharmaceutical Co , Alison Rash , Connecticut Hematology , Oncology Associates , China Based Qilu Pharmaceutical , Yale Smilow Cancer Hospital , Hartford Healthcare Cancer Hospital , Us Drug Shortage , Cancer Treatment , Generic Drug Crisis , Healthcare Rationing , Overseas Drug Import ,

BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August

(1)
BASEL (dpa-AFX) - Today s Daily Dose brings you news about temporary suspension of bluebird bio s gene therapy trials in sickle cell disease, Sesen Bio s regulatory catalyst for this year, partial hold on Cortexyme s open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer s disease, and expanded FDA approval of Novartis Entresto.
Read on.
1. Sickle Cell Disease Trial Blues For bluebird bio
Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company s LentiGlobin gene therapy trials for sickle cell disease were temporarily suspended after two cases of cancer were reported in study participants. ....

United States , Hong Kong , United Kingdom , Bacille Calmette Guerin , Novarti Entresto , Cortexyme Inc , Genetic Technologies Corp , Inhibrx Inc , Clene Inc , Diffusion Pharmaceuticals Inc , Akers Biosciences Inc , European Union , Neptune Wellness Solutions Inc , European Medicines Agency , Timber Pharmaceuticals Inc , Daily Dose , Sesen Bio , Cell Disease Trial Blues For , Suspected Unexpected Serious Adverse Reaction , Partial Hold On Cortexyme , Pharma Hits New , Diffusion Pharmaceuticals , Expanded Label , Bio To Face , Biologics License Application , Pseudomonas Exotoxin ,